NEW BRUNSWICK, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. (“Senesco” or the “Company”) reported today that certain insiders of Senesco Technologies, Inc., a Delaware corporation, purchased all of the convertible debentures, warrants and common stock of the Company which are held by Stanford Venture Capital Holdings, Inc.
About Senesco Technologies, Inc.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and joint ventures; the success of the Company’s license agreements; the successful conversion of the Company’s letter of intent into a license agreement; the acceptance by the market of the Company’s products; success of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
CONTACT: Jack Van Hulst, Chief Executive Officer, Senesco Technologies,
Inc., +1-732-296-8400, jvanhulst@senesco.com; or Brian Ritchie, FD,
+1-212-850-5600, brian.ritchie@fd.com
